In September 2005, a Motion for authorization to institute a class action was filed with the Superior Court of Quebec on behalf of all persons resident in Canada having used Depo-Provera.
Depo-Provera is a contraceptive marketed by Pfizer in the form of an injection. An injection of Depo-Provera provides protection against pregnancy for three (3) months. Women who use it for this purpose therefore receive four (4) injections per year. Depo-Provera is also used in the treatment of endometriosis, recurrent or metastatic endometre or kidney cell cancer as well as in the treatment of recurrent, inoperable or metastatic breast cancer in menopausal women. Depo-Provera has been widely prescribed in Canada.
On June 30th, 2005, Pfizer admitted in the context of a public notice that two (2) clinical studies indicate that women using Depo-Provera may be subject to a considerable reduction in their bone mineral density. The bone loss observed is proportionate to the length of usage and may not be entirely reversible. This finding is particularly preoccupying in the case of adolescents whose mineral bone density should rather increase. The reduction in mineral bone density can lead to osteoporosis and increase the risk of fractures, particularly for menopausal women. Depo-Provera is still distributed in Canada.
On May 28th, 2008, the Honourable Danielle Grenier, S.C.J., granted the Motion for authorization to institute a class action for the class described below.
You are part of the class in the context of the present case if you correspond to the following:
[Translation] "Any person domiciled in Canada who claims to be suffering or to have suffered a reduction of its bone mineral density as a result of her or his use of DEPO-PROVERA."
If you are part of this class, we invite you to register yourself as one of its members. This way, we will communicate with you whenever there are important developments in this file.
We also invite you to consult the Notice to Depo-Provera users of the authorization of a class action.
A Class Action is instituted against the Pfizer Canada Inc. and Pfizer Inc.
The Superior Court of Quebec approves the content of the notices and their distribution to members of the class.
The Superior Court of Quebec authorizes the class action.
From February 4 to February 8, 2008, the Motion for Authorization to Institute a Class Action is argued before the Superior Court. The matter is taken under advisement.
Justice Grenier, s.c.j., dismisses Pfizer's Motions for leave to adduce evidence in the Court record as well as to examine petitioner.
Filing of the Motion for authorization to institute a class action.